Wilson Andrés Vásconez Samaniego: Decentralization of Clinical Trials Is Becoming a Reality – A Key Takeaway from ASH-FDA Workshop
Wilson Andrés Vásconez Samaniego, Assistant Professor at University of Arizona College of Medicine – Phoenix, reposted from ASH on LinkedIn:
”Just wrapped today at the ASH–FDA Workshop, where the focus was on how to make clinical trials more inclusive and accessible.
A key takeaway: decentralization of clinical trials is no longer just an idea—it’s becoming a reality.
By leveraging innovative trial designs and regulatory flexibility, we have the chance to expand access, reduce barriers, and increase inclusion for patients with rare pediatric oncology diseases and sickle cell disease.
Grateful to see American Society of Hematology and the FDA leading these important discussions, and excited about what this means for the future of hematology, oncology, and cell/gene therapies.”
American Society of Hematology (ASH) shared on LinkedIn:
”Thank you FDA for joining the American Society of Hematology in co-hosting the FDA-ASH Collaboration: A Workshop on Regulatory Science in Hematology!
Over the past two days, 20 select participants explored the FDA’s role in hematology product development through interactive panels and case-based discussions.
This unique opportunity fostered meaningful dialogue between ASH members and FDA staff on key regulatory issues in hematology drug development.
Learn more”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed
-
Jan 12, 2026, 01:35Nirav Dhanesha Shares The Lab’s Latest Publication on Neutrophil CD14 and DVT Link